144 related articles for article (PubMed ID: 6831625)
1. Time dependency of adriamycin and adriamycinol kinetics.
Gil P; Favre R; Durand A; Iliadis A; Cano JP; Carcassonne Y
Cancer Chemother Pharmacol; 1983; 10(2):120-4. PubMed ID: 6831625
[TBL] [Abstract][Full Text] [Related]
2. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.
Leca F; Marchiset-Leca D; Noble A; Antonetti M
Eur J Drug Metab Pharmacokinet; 1991; 16(2):107-11. PubMed ID: 1936069
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
[TBL] [Abstract][Full Text] [Related]
4. Mathematical model for adriamycin (doxorubicin) pharmacokinetics.
Reich SD; Steinberg F; Bachur NR; Riggs CE; Goebel R; Berman M
Cancer Chemother Pharmacol; 1979; 3(2):125-31. PubMed ID: 509697
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
Miller AA; Schmidt CG
Cancer Res; 1987 Mar; 47(5):1461-5. PubMed ID: 3815348
[TBL] [Abstract][Full Text] [Related]
6. A rapid chromatographic procedure for the determination of adriamycin, daunomycin and their 13-OH metabolites adriamycinol and daunomycinol.
Erb N; Erttmann R; Landbeck G
Cancer Chemother Pharmacol; 1986; 17(1):53-5. PubMed ID: 3698178
[TBL] [Abstract][Full Text] [Related]
7. Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.
Chlebowski RT; Chan KK; Tong MJ; Weiner JM; Ryden VM; Bateman JR
Cancer; 1981 Sep; 48(5):1088-95. PubMed ID: 6268277
[TBL] [Abstract][Full Text] [Related]
8. Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.
Eksborg S; Ehrsson H; Andersson I
J Chromatogr; 1979 Dec; 164(4):479-86. PubMed ID: 541423
[TBL] [Abstract][Full Text] [Related]
9. Bilary disposition of adriamycin.
Riggs CE; Benjamin RS; Serpick AA; Bachur NR
Clin Pharmacol Ther; 1977 Aug; 22(2):234-41. PubMed ID: 884924
[TBL] [Abstract][Full Text] [Related]
10. Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites.
Preiss R; Sohr R; Kittelmann B; Müller E; Haase D
Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):156-64. PubMed ID: 2714916
[TBL] [Abstract][Full Text] [Related]
11. [The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].
Ehninger G; Stocker HJ; Proksch B; Wilms K
Klin Wochenschr; 1980 Sep; 58(18):927-34. PubMed ID: 7206588
[TBL] [Abstract][Full Text] [Related]
12. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
Cummings J; Stuart JF; Calman KC
J Chromatogr; 1984 Nov; 311(1):125-33. PubMed ID: 6520153
[TBL] [Abstract][Full Text] [Related]
13. Analysis of adriamycin and adriamycinol in micro volumes of rat plasma.
Bots AM; Van Oort WJ; Noordhoek J; Van Dijk A; Klein SW; Van Hoesel QG
J Chromatogr; 1983 Feb; 272(2):421-7. PubMed ID: 6833441
[No Abstract] [Full Text] [Related]
14. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.
Jacquet JM; Bressolle F; Galtier M; Bourrier M; Donadio D; Jourdan J; Rossi JF
Cancer Chemother Pharmacol; 1990; 27(3):219-25. PubMed ID: 2265458
[TBL] [Abstract][Full Text] [Related]
15. Rapid distribution of adriamycin in the ascitic and pleural fluid of women with ovarian carcinomas.
Lazo JS; Schwartz PE
Gynecol Oncol; 1985 May; 21(1):65-72. PubMed ID: 3988127
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.
Eksborg S; Cedermark BJ; Strandler HS
Med Oncol Tumor Pharmacother; 1985; 2(1):47-54. PubMed ID: 4058077
[TBL] [Abstract][Full Text] [Related]
17. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.
Cummings J; Milstead R; Cunningham D; Kaye S
Eur J Cancer Clin Oncol; 1986 Aug; 22(8):991-1001. PubMed ID: 3770056
[TBL] [Abstract][Full Text] [Related]
18. Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography.
Andrews PA; Brenner DE; Chou FT; Kubo H; Bachur NR
Drug Metab Dispos; 1980; 8(3):152-6. PubMed ID: 6104578
[TBL] [Abstract][Full Text] [Related]
19. Measurement of adriamycin (doxorubicin) and its metabolites in human plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.
Pierce RN; Jatlow PI
J Chromatogr; 1979 Dec; 164(4):471-8. PubMed ID: 541422
[TBL] [Abstract][Full Text] [Related]
20. Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS).
Cummings J; Merry S; Willmott N
Eur J Cancer Clin Oncol; 1986 Apr; 22(4):451-60. PubMed ID: 3460809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
